<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10089140" created="12/05/2006" creator="Yo Shidahara"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>10089140</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Reduction of <cons id="C1" lex="(AND tumour_necrosis_factor_alpha_expression tumour_necrosis_factor_alpha_signalling)" sem="(AND Other Other)"><frag id="F1">tumour necrosis factor alpha</frag> <frag id="F2">expression</frag> and <frag id="F3">signalling</frag></cons> in <term id="T3" lex="peripheral_blood_mononuclear_cell" sem="Cell_natural">peripheral blood mononuclear cells</term> from <term id="T4" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T5" lex="thalassaemia" sem="Other">thalassaemia</term> or <term id="T6" lex="sickle_cell_anaemia" sem="Other">sickle cell anaemia</term> upon treatment with <term id="T7" lex="desferrioxamine" sem="Organic_compound_other">desferrioxamine</term>.</sentence>
<event KT="Other" id="E1">
<type class="Gene_expression"/>
<theme idref="F1"/>
<clue>Reduction of tumour necrosis factor alpha <clueType>expression</clueType> and signalling in peripheral blood mononuclear cells from patients with thalassaemia or sickle cell anaemia upon treatment with desferrioxamine.</clue>
</event>
<event KT="Other" id="E2">
<type class="Cell_communication"/>
<theme idref="F1"/>
<clue>Reduction of tumour necrosis factor alpha expression and <clueType>signalling</clueType> in peripheral blood mononuclear cells from patients with thalassaemia or sickle cell anaemia upon treatment with desferrioxamine.</clue>
</event>
<event KT="Investigation" id="E3">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<cause idref="T7"/>
<clue><clueType>Reduction</clueType> <linkTheme>of</linkTheme> tumour necrosis factor alpha expression and signalling <clueLoc>in peripheral blood mononuclear cells from patients with thalassaemia</clueLoc> or sickle cell anaemia <linkCause>upon treatment with</linkCause> desferrioxamine.</clue>
</event>
<event KT="Investigation" id="E103">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<cause idref="T7"/>
<clue><clueType>Reduction</clueType> <linkTheme>of</linkTheme> tumour necrosis factor alpha expression and signalling <clueLoc>in peripheral blood mononuclear cells from patients with</clueLoc> thalassaemia or <clueLoc>sickle cell anaemia</clueLoc> <linkCause>upon treatment with</linkCause> desferrioxamine.</clue>
</event>
<event KT="Investigation" id="E4">
<type class="Negative_regulation"/>
<theme idref="E2"/>
<cause idref="T7"/>
<clue><clueType>Reduction</clueType> <linkTheme>of</linkTheme> tumour necrosis factor alpha expression and signalling <clueLoc>in peripheral blood mononuclear cells from patients with thalassaemia</clueLoc> or sickle cell anaemia <linkCause>upon treatment with</linkCause> desferrioxamine.</clue>
</event>
<event KT="Investigation" id="E104">
<type class="Negative_regulation"/>
<theme idref="E2"/>
<cause idref="T7"/>
<clue><clueType>Reduction</clueType> <linkTheme>of</linkTheme> tumour necrosis factor alpha expression and signalling <clueLoc>in peripheral blood mononuclear cells from patients with</clueLoc> thalassaemia or <clueLoc>sickle cell anaemia</clueLoc> <linkCause>upon treatment with</linkCause> desferrioxamine.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Recent evidence indicates that the rate of progression of the <term id="T8" lex="HIV-1_disease" sem="Other"><term id="T9" lex="HIV-1" sem="Virus">HIV-1</term> disease</term> is significantly reduced in <term id="T10" lex="thalassaemia" sem="Other">thalassaemia</term> major <term id="T11" lex="patient" sem="Multicellular_organism_natural">patients</term> upon treatment with high doses of <term id="T12" lex="desferrioxamine" sem="Organic_compound_other">desferrioxamine</term> (<term id="A1" sem="Organic_compound_other">DFX</term>).</sentence>
<event KT="Other" id="E5">
<type class="Positive_regulation"/>
<theme idref="T8"/>
<clue>Recent evidence indicates that the rate of <clueType>progression</clueType> <linkTheme>of</linkTheme> the HIV-1 disease is significantly reduced in thalassaemia major patients upon treatment with high doses of desferrioxamine (DFX).</clue>
</event>
<event CL="L2" KT="Analysis" Manner="High" Source="Other" id="E6">
<type class="Negative_regulation"/>
<theme idref="E5"/>
<cause idref="A1"/>
<clue><clueSource>Recent</clueSource> <clueKT>evidence</clueKT> <clueCL>indicates</clueCL> that the rate of progression of the HIV-1 disease is <clueManner>significantly</clueManner> <clueType>reduced</clueType> <clueLoc>in thalassaemia major patients</clueLoc> <linkCause>upon treatment with</linkCause> high doses of desferrioxamine (DFX).</clue>
</event>
<sentence id="S3">The authors have previously demonstrated that in vitro exposure of <term id="T13" lex="mononuclear_cell" sem="Cell_natural">mononuclear cells</term> to <term id="T14" lex="DFX" sem="Organic_compound_other">DFX</term> decreases the bioavailability of <term id="T15" lex="tumour_necrosis_factor_alpha" sem="Protein_molecule">tumour necrosis factor alpha</term> (<term id="T16" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term>) which has a stimulatory effect on <term id="T17" lex="HIV-1_replication" sem="Other"><term id="T18" lex="HIV-1" sem="Virus">HIV-1</term> replication</term>.</sentence>
<event KT="Analysis" Source="Other" id="E8">
<type class="Negative_regulation"/>
<theme idref="T16"/>
<cause idref="T14"/>
<clue>The authors have <clueSource>previously</clueSource> <clueKT>demonstrated</clueKT> that in vitro <linkCause>exposure</linkCause> of <clueLoc>mononuclear cells</clueLoc> <linkCause>to</linkCause> DFX <clueType>decreases</clueType> the bioavailability of tumour necrosis factor alpha (TNF-alpha) which has a stimulatory effect on HIV-1 replication.</clue>
</event>
<event KT="Other" id="E9">
<type class="Viral_life_cycle"/>
<theme idref="T18"/>
<clue>The authors have previously demonstrated that in vitro exposure of mononuclear cells to DFX decreases the bioavailability of tumour necrosis factor alpha (TNF-alpha) which has a stimulatory effect on HIV-1 <clueType>replication</clueType>.</clue>
</event>
<event KT="Analysis" Source="Other" id="E10">
<type class="Positive_regulation"/>
<theme idref="E9"/>
<cause idref="T16"/>
<clue>The authors have <clueSource>previously</clueSource> <clueKT>demonstrated</clueKT> that in vitro exposure of mononuclear cells to DFX decreases the bioavailability of tumour necrosis factor alpha (TNF-alpha) which <clueType>has</clueType> a <clueType>stimulatory effect</clueType> on HIV-1 replication.</clue>
</event>
<sentence id="S4">In this study, therefore, <term id="T19" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> bioavailability from <term id="T20" lex="mononuclear_cell" sem="Cell_natural">mononuclear cells</term> isolated from 10 <term id="T21" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T22" lex="thalassaemia" sem="Other">thalassaemia</term> or <term id="T23" lex="sickle_cell_anaemia" sem="Other">sickle cell anaemia</term> given <term id="T24" lex="DFX" sem="Organic_compound_other">DFX</term> as compared to 10 <term id="T25" lex="untreated_subject" sem="Multicellular_organism_natural">untreated subjects</term> has been evaluated.</sentence>
<sentence id="S5">Evidence is presented showing that <term id="T26" lex="DFX" sem="Organic_compound_other">DFX</term> treatment reduces <term id="T27" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> bioavailability (P&lt;0.05) by inhibiting its steady state (P&lt;0.05) and by enhancing its inactivation through binding to soluble <term id="A2" sem="Protein_molecule"><term id="T28" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> receptor type II</term> (P&lt;0.05).</sentence>
<event KT="Analysis" id="E11">
<type class="Negative_regulation"/>
<theme idref="T27"/>
<cause idref="T26"/>
<clue><clueKT>Evidence</clueKT> is <clueKT>presented</clueKT> <clueKT>showing</clueKT> that DFX treatment <clueType>reduces</clueType> TNF-alpha bioavailability (P&lt;0.05) by inhibiting its steady state (P&lt;0.05) and by enhancing its inactivation through binding to soluble TNF-alpha receptor type II (P&lt;0.05).</clue>
</event>
<event KT="Other" id="E12">
<type class="Binding"/>
<theme idref="T26"/>
<theme idref="A2"/>
<clue>Evidence is presented showing that DFX treatment reduces TNF-alpha bioavailability (P&lt;0.05) by inhibiting its steady state (P&lt;0.05) and by enhancing its inactivation through <clueType>binding</clueType> <linkTheme>to</linkTheme> soluble TNF-alpha receptor type II (P&lt;0.05).</clue>
</event>
<event KT="Other" id="E13">
<type class="Negative_regulation"/>
<theme idref="T27"/>
<clue>Evidence is presented showing that DFX treatment reduces TNF-alpha bioavailability (P&lt;0.05) by inhibiting its steady state (P&lt;0.05) and by enhancing <corefTheme>its</corefTheme> <clueType>inactivation</clueType> through binding to soluble TNF-alpha receptor type II (P&lt;0.05).</clue>
</event>
<event KT="Other" id="E14">
<type class="Positive_regulation"/>
<theme idref="E13"/>
<cause idref="E12"/>
<clue>Evidence is presented showing that DFX treatment reduces TNF-alpha bioavailability (P&lt;0.05) by inhibiting its steady state (P&lt;0.05) and by <clueType>enhancing</clueType> its inactivation <linkCause>through</linkCause> binding to soluble TNF-alpha receptor type II (P&lt;0.05).</clue>
</event>
<sentence id="S6">We also show that <term id="T29" lex="DFX" sem="Organic_compound_other">DFX</term> treatment limits the <term id="T30" lex="in_vivo_activation" sem="Other">in vivo activation</term> of <term id="T31" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term>, a <term id="T32" lex="transcription_factor" sem="Protein_family_or_group">transcription factor</term> involved in both <term id="T33" lex="TNF-alpha_gene_transcriptio" sem="Other"><term id="T34" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> gene transcription</term> and <term id="T1" sem="Other"><term id="T35" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> signalling</term> (P&lt;0.005).</sentence>
<event KT="Other" id="E15">
<type class="Positive_regulation"/>
<theme idref="T31"/>
<clue>We also show that DFX treatment limits the in vivo <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappaB, a transcription factor involved in both TNF-alpha gene transcription and TNF-alpha signalling (P&lt;0.005).</clue>
</event>
<event KT="Analysis" id="E101">
<type class="Negative_regulation"/>
<theme idref="E15"/>
<cause idref="T29"/>
<clue>We also <clueKT>show</clueKT> that DFX treatment <clueType>limits</clueType> the in vivo activation of NF-kappaB, a transcription factor involved in both TNF-alpha gene transcription and TNF-alpha signalling (P&lt;0.005).</clue>
</event>
<event KT="Other" id="E16">
<type class="Transcription"/>
<theme idref="T34"/>
<clue>We also show that DFX treatment limits the in vivo activation of NF-kappaB, a transcription factor involved in both TNF-alpha gene <clueType>transcription</clueType> and TNF-alpha signalling (P&lt;0.005).</clue>
</event>
<event KT="Other" id="E17">
<type class="Cell_communication"/>
<theme idref="T34"/>
<clue>We also show that DFX treatment limits the in vivo activation of NF-kappaB, a transcription factor involved in both TNF-alpha gene transcription and TNF-alpha <clueType>signalling</clueType> (P&lt;0.005).</clue>
</event>
<event KT="Fact" id="E18">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T31"/>
<clue>We also show that DFX treatment limits the in vivo activation of NF-kappaB, <corefCause>a transcription factor</corefCause> <clueType>involved</clueType> <linkTheme>in</linkTheme> both TNF-alpha gene transcription and TNF-alpha signalling (P&lt;0.005).</clue>
</event>
<event KT="Fact" id="E19">
<type class="Correlation"/>
<theme idref="T31"/>
<theme idref="E17"/>
<clue>We also show that DFX treatment limits the in vivo activation of NF-kappaB, <corefCause>a transcription factor</corefCause> <clueType>involved</clueType> <linkTheme>in</linkTheme> both TNF-alpha gene transcription and TNF-alpha signalling (P&lt;0.005).</clue>
</event>
<sentence id="S7">We conclude that <term id="T36" lex="TNF-alpha_bioavailability" sem="Other"><term id="T37" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> bioavailability</term> and signalling are impaired in <term id="T38" lex="patient" sem="Multicellular_organism_natural">patients</term> upon <term id="T2" sem="Other"><term id="T39" lex="DFX" sem="Organic_compound_other">DFX</term> treatment</term>.</sentence>
<event KT="Other" id="E20">
<type class="Negative_regulation"/>
<theme idref="T37"/>
<cause idref="T39"/>
<clue>We conclude that TNF-alpha bioavailability and signalling are <clueType>impaired</clueType> <clueLoc>in patients</clueLoc> <linkCause>upon</linkCause> DFX treatment.</clue>
</event>
<event KT="Other" id="E25">
<type class="Cell_communication"/>
<theme idref="T37"/>
<clue>We conclude that TNF-alpha bioavailability and <clueType>signalling</clueType> are impaired in patients upon DFX treatment.</clue>
</event>
<event KT="Analysis" id="E26">
<type class="Negative_regulation"/>
<theme idref="E25"/>
<cause idref="T39"/>
<clue>We <clueKT>conclude</clueKT> that TNF-alpha bioavailability and signalling are <clueType>impaired</clueType> <clueLoc>in patients</clueLoc> <linkCause>upon</linkCause> DFX treatment.</clue>
</event>
<sentence id="S8">This mechanism may contribute to delayed progression of the <term id="T40" lex="HIV-1_infection" sem="Other"><term id="T41" lex="HIV-1" sem="Virus">HIV-1</term> infection</term> in vivo.</sentence>
<event KT="Other" id="E21">
<type class="Initiation_of_viral_infection"/>
<theme idref="T41"/>
<clue>This mechanism may contribute to delayed progression of the HIV-1 <clueType>infection</clueType> in vivo.</clue>
</event>
<event KT="Other" id="E22">
<type class="Positive_regulation"/>
<theme idref="E21"/>
<clue>This mechanism may contribute to delayed <clueType>progression</clueType> <linkTheme>of</linkTheme> the HIV-1 infection in vivo.</clue>
</event>
<event KT="Other" id="E23">
<type class="Negative_regulation"/>
<theme idref="E22"/>
<clue>This mechanism may contribute to <clueType>delayed</clueType> progression of the HIV-1 infection in vivo.</clue>
</event>
<event CL="L1" KT="Analysis" id="E24">
<type class="Positive_regulation"/>
<theme idref="E23"/>
<cause idref="E20"/>
<clue>This mechanism <clueCL>may</clueCL> <clueKT>contribute</clueKT> to delayed progression of the HIV-1 infection in vivo.</clue>
</event>
<sentence id="S9">Copyright 1999 Academic Press.</sentence>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
